Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with nelson syndrome

Endocrine Pathology

Volumn 21, Issue 4, 2010, Pages 227-229

  Salehi, Fateme ^a   Scheithauer, Bernd W ^d   Moyes, Veronica J ^b   Drake, William M ^b   Syro, Luis V ^c   Manoranjan, Branavan ^a   Sharma, Soniya ^a   Horvath, Eva ^a   Kovacs, Kalman ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^d NONE

Author keywords

ACTH tumors; Cushing's disease; MGMT; Nelson syndrome; Pituitary tumor

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ACTH SECRETING ADENOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NELSON SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX RATIO;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NELSON SYNDROME; TUMOR SUPPRESSOR PROTEINS;

EID: 78650872256     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-010-9138-3     Document Type: Article

References (14)

1. VJ Moyes G Alusi HI Sabin J Evanson DM Berney K Kovacs, et al. 2009 Treatment of Nelson's syndrome with temozolomide Eur J Endocrinol 160 115 119 1:CAS:528:DC%2BD1MXhsVOhsb%2FJ 10.1530/EJE-08-0557 18984772
2. K Kovacs E Horvath LV Syro H Uribe LC Penagos LD Ortiz, et al. 2007 Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings Hum Pathol 38 185 189 1:CAS:528: DC%2BD28XhtleisrfE 10.1016/j.humpath.2006.07.014 17056093 (Pubitemid 44880216)
3. S Vidal K Kovacs E Horvath BW Scheithauer T Kuroki RV Lloyd 2001 Microvessel density in pituitary adenomas and carcinomas Virchows Arch 438 595 602 1:CAS:528:DC%2BD3MXkt1Kksbk%3D 10.1007/s004280000373 11469692 (Pubitemid 32662379)
4. K Kovacs BW Scheithauer M Lombardero RE McLendon LV Syro H Uribe, et al. 2008 MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy Acta Neuropathol 115 261 262 10.1007/s00401-007-0279-5 17926052
5. S Mohammed K Kovacs W Mason H Smyth MD Cusimano 2009 Use of temozolomide in aggressive pituitary tumors: case report Neurosurgery 64 E773 774 10.1227/01.NEU.0000339115.12803.4E 19349807
6. LV Syro H Uribe LC Penagos LD Ortiz CE Fadul E Horvath, et al. 2006 Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm Clin Endocrinol (Oxf) 65 552 553 10.1111/j.1365-2265.2006.02653.x (Pubitemid 44414285)
7. I Casorelli MT Russo M Bignami 2008 Role of mismatch repair and MGMT in response to anticancer therapies Anticancer Agents Med Chem 8 368 380 1:CAS:528:DC%2BD1cXkvV2iuro%3D 18473722
8. M Nagane K Kobayashi A Ohnishi S Shimizu Y Shiokawa 2007 Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide Jpn J Clin Oncol 37 897 906 10.1093/jjco/hym132 18156172 (Pubitemid 351176479)
9. IF Pollack RL Hamilton RW Sobol J Burnham AJ Yates EJ Holmes, et al. 2006 O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort J Clin Oncol 24 3431 3437 1:CAS:528:DC%2BD28Xot1KisLo%3D 10.1200/JCO.2006.05.7265 16849758 (Pubitemid 46638900)
10. OL Chinot M Barrie S Fuentes N Eudes S Lancelot P Metellus, et al. 2007 Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide J Clin Oncol 25 1470 1475 1:CAS:528:DC%2BD2sXlsVyntbo%3D 10.1200/JCO.2006.07.4807 17442989 (Pubitemid 46733073)
11. ME Hegi AC Diserens T Gorlia MF Hamou N de Tribolet M Weller, et al. 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 1:CAS:528:DC%2BD2MXit1Wktro%3D 10.1056/NEJMoa043331 15758010 (Pubitemid 40349502)
12. MJ Banasiak AR Malek 2007 Nelson syndrome: comprehensive review of pathophysiology, diagnosis, and management Neurosurg Focus 23 E13 10.3171/foc.2007.23.3.15 17961028
13. AI McCormack KL McDonald AJ Gill SJ Clark MG Burt KA Campbell, et al. 2009 Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours Clin Endocrinol (Oxf) 71 226 233 1:CAS:528:DC%2BD1MXhtVSqt7bJ 10.1111/j.1365-2265.2008.03487.x
14. LV Syro BW Scheithauer LD Ortiz CE Fadul E Horvath F Rotondo, et al. 2009 Effect of temozolomide in a patient with recurring oncocytic gonadotroph pituitary adenoma Hormone (Athens) 8 303 306